Xtrapel 100 mg Injection should be administered slowly over 2-3 minutes if given intravenously, or deep intramuscularly if given IM. Do not mix with other medications in the same syringe.

Xtrapel selectively modulates neuronal pain pathways in the central nervous system, reducing the transmission of pain signals without acting on opioid receptors. It also exhibits mild anti-inflammatory properties by inhibiting certain inflammatory mediators at the site of injury.

• •Hypersensitivity to Xtrapel or any component of the formulation
• •Severe hepatic or renal impairment
• •Acute porphyria

Store below 30°C in a dry place, protected from light. Do not freeze. Keep out of reach of children.

Symptoms of overdose may include severe dizziness, drowsiness, confusion, nausea, vomiting, and potentially seizures. Treatment is symptomatic and supportive, including gastric lavage (if oral intake), activated charcoal, and maintaining vital functions. There is no specific antidote.

Use in pregnancy should be avoided unless clearly necessary, as safety has not been established. It is not known if Xtrapel is excreted in breast milk; therefore, caution should be exercised when administered to a nursing mother.